RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
AgeX Therapeutics Stock

AgeX Therapeutics Stocks 2024

AgeX Therapeutics Stocks

1.08 M

Ticker

SER

ISIN

US00848H1086

WKN

A2N8PC

In 2024, AgeX Therapeutics had 1.08 M outstanding stocks, a -97.16% change from the 37.95 M stocks in the previous year.

The AgeX Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
20231.08
202237.95
202137.89
202037.67
201937.27
201834.91
201735.83
201635.83

AgeX Therapeutics shares outstanding

The number of shares was AgeX Therapeutics in 2023 — This indicates how many shares 1.079 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AgeX Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AgeX Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AgeX Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AgeX Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AgeX Therapeutics Aktienanalyse

What does AgeX Therapeutics do?

AgeX Therapeutics Inc is an emerging biopharmaceutical company focused on researching and developing innovative therapies to combat the aging process and related diseases. The company was founded in 2017 by Michael D. West, one of the most renowned pioneers in the field of regenerative medicine and stem cell research. AgeX Therapeutics' business model is based on utilizing groundbreaking knowledge in regenerative medicine, genomics, and cryobiology to develop new treatment methods that enable longer lifespan and higher quality of life. The company has developed a wide range of products and services focused on tissue and organ regeneration and repair. One of AgeX Therapeutics' main branches is the development of human embryonic stem cells (hES cells), which can be used as starting material for the production of cells and tissues. These cells have the potential to transform into any type of cell or tissue, making them a revolutionary tool in regenerative medicine. AgeX Therapeutics works closely with other companies and research institutions to further improve its hES cell technology and find new ways to implement it in practical applications. Another important area of AgeX Therapeutics is targeted genome editing, a procedure for modifying the genetic material of cells and organisms. This procedure can be used to correct genetic defects, treat diseases, or slow down the aging process. AgeX Therapeutics has developed its own technology platform to make targeted genome editing procedures more efficient and precise. AgeX Therapeutics' products and services also include bioelectric medicine, targeted senescence induction, and cryobiological storage. Bioelectric medicine utilizes electrical currents to promote tissue regeneration, while targeted senescence induction aims to selectively kill aging cells, thus slowing down the aging process. Cryobiological storage is a method for long-term storage of biological materials at extremely low temperatures to protect them from degradation and degeneration. AgeX Therapeutics is an ambitious company striving to expand the boundaries of regenerative medicine and discover new therapy options that improve people's quality of life. The company is financially stable and has a highly qualified team of scientists and medical professionals dedicated to achieving these goals. With its sophisticated technology platform and wide range of products and services, AgeX Therapeutics is well positioned to succeed in the rapidly growing market of regenerative medicine. AgeX Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating AgeX Therapeutics's Shares Outstanding

AgeX Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in AgeX Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding AgeX Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in AgeX Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about AgeX Therapeutics stock

How many stocks are there of AgeX Therapeutics?

The current number of stocks of AgeX Therapeutics is 1.08 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of AgeX Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of AgeX Therapeutics evolved in recent years?

The number of shares of AgeX Therapeutics has increased by -97.16% gesunken compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. AgeX Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of AgeX Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does AgeX Therapeutics pay?

Over the past 12 months, AgeX Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AgeX Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of AgeX Therapeutics?

The current dividend yield of AgeX Therapeutics is .

When does AgeX Therapeutics pay dividends?

AgeX Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AgeX Therapeutics?

AgeX Therapeutics paid dividends every year for the past 0 years.

What is the dividend of AgeX Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is AgeX Therapeutics located?

AgeX Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von AgeX Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AgeX Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did AgeX Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of AgeX Therapeutics in the year 2023?

In the year 2023, AgeX Therapeutics distributed 0 USD as dividends.

In which currency does AgeX Therapeutics pay out the dividend?

The dividends of AgeX Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von AgeX Therapeutics

Our stock analysis for AgeX Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AgeX Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.